ONC
BeOne Medicines Ltd. NASDAQ Listed Feb 2, 2016$317.12
Mkt Cap $33.9B
52w Low $218.31
59.2% of range
52w High $385.22
50d MA $300.67
200d MA $320.70
P/E (TTM)
8.6x
EV/EBITDA
49.6x
P/B
7.3x
Debt/Equity
0.5x
ROE
6.6%
P/FCF
35.2x
RSI (14)
—
ATR (14)
—
Beta
0.54
50d MA
$300.67
200d MA
$320.70
Avg Volume
242.7K
BeOne Medicines, formerly known as BeiGene, is a global oncology company focused on discovering, developing, and commercializing innovative cancer therapies. Founded in 2010 and headquartered in Cambridge, Massachusetts—with operations spanning over 45 countries across six continents—the company rebranded as BeOne in late 2024 and redomiciled to Basel, Switzerland in 2025. BeOne has established itself as a leader in immuno-oncology and targeted therapies, with key assets including Tevimbra (tislelizumab), a PD-1 monoclonal antibody approved for multiple cancer indications globally, and Brukinsa (zanubrutinib), a Bruton's tyrosine kinase (BTK) inhibitor that surpassed $1.3 billion in annual sales and is approved in major markets such as the U.S., Europe, and China. The company’s strategy combines internal R&D with the development of assets sourced from external partnerships, driving a robust pipeline across hematologic malignancies and solid tumors.
C/O BEONE MEDICINES I GMBH · BASEL 4051 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | TNS | 0.81 | 26.65 | +3206.5% | 313.32 | +0.2% | +1.2% | — | — | — | — | — |
| Feb 26, 2026 | TNS | 1.60 | 0.58 | -63.8% | 322.37 | -1.2% | -1.7% | -0.8% | -5.5% | +0.7% | -2.0% | — |
| Nov 6, 2025 | TNS | 0.72 | 1.09 | +51.4% | 332.36 | -5.1% | -3.7% | +2.9% | +4.4% | +9.8% | -2.4% | — |
| Aug 6, 2025 | TNS | 0.48 | 0.84 | +75.0% | 298.52 | -0.4% | -0.1% | -3.4% | +0.5% | -0.6% | +6.7% | — |
| May 7, 2025 | TNS | -0.71 | 1.22 | +271.8% | 232.25 | +1.7% | +1.6% | -1.7% | +0.5% | -3.7% | -2.1% | — |
| Feb 27, 2025 | TNS | -0.88 | -1.43 | -62.5% | 278.38 | -2.9% | -2.4% | -9.7% | +4.8% | +1.9% | -2.0% | — |
| Nov 12, 2024 | TNS | -0.88 | -1.15 | -30.7% | 193.64 | +2.0% | +0.9% | -1.1% | -2.1% | -0.8% | +0.0% | — |
| Aug 7, 2024 | TNS | -2.10 | -1.15 | +45.2% | 176.73 | +1.2% | +3.6% | -0.1% | +4.0% | -1.5% | -0.3% | — |
| Mar 31, 2024 | TNS | — | -2.41 | — | 156.39 | — | — | +1.8% | -3.8% | -0.8% | -1.6% | — |
| Dec 31, 2023 | TNS | — | -25.53 | — | 180.36 | — | — | -1.9% | +2.5% | -3.2% | -5.9% | — |
| Sep 30, 2023 | TNS | — | 2.01 | — | 179.87 | — | — | -0.8% | -2.4% | -2.9% | +0.9% | — |
| Jun 30, 2023 | TNS | — | -3.64 | — | 178.30 | +0.3% | +1.4% | +5.9% | -1.1% | +0.1% | +1.6% | — |
| Mar 31, 2023 | BMO | — | -3.34 | — | 215.53 | +0.0% | -1.2% | +1.0% | -1.4% | +12.5% | -1.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 16 | Jefferies | Downgrade | Buy → Hold | — | $284.05 | $286.11 | +0.7% | +2.0% | -0.8% | -1.8% | +0.2% | -2.6% |
| Feb 27 | Barclays | Maintains | Overweight → Overweight | — | $322.37 | $318.66 | -1.2% | -1.7% | -0.8% | -5.5% | +0.7% | -2.0% |
| Feb 27 | Truist | Maintains | Buy → Buy | — | $322.37 | $318.66 | -1.2% | -1.7% | -0.8% | -5.5% | +0.7% | -2.0% |
| Feb 27 | RBC Capital | Maintains | Outperform → Outperform | — | $322.37 | $318.66 | -1.2% | -1.7% | -0.8% | -5.5% | +0.7% | -2.0% |
| Feb 27 | Guggenheim | Maintains | Buy → Buy | — | $322.37 | $318.66 | -1.2% | -1.7% | -0.8% | -5.5% | +0.7% | -2.0% |
| Feb 4 | Barclays | Maintains | Overweight → Overweight | — | $346.38 | $348.79 | +0.7% | +1.6% | -1.4% | +2.0% | -1.4% | +1.3% |
| Nov 18 | RBC Capital | Maintains | Outperform → Outperform | — | $376.63 | $362.46 | -3.8% | -3.4% | -2.8% | -1.3% | -0.4% | -4.3% |
| Nov 10 | Citigroup | Maintains | Buy → Buy | — | $319.97 | $329.00 | +2.8% | +2.9% | +4.4% | +9.8% | -2.4% | -0.7% |
| Nov 7 | RBC Capital | Maintains | Outperform → Outperform | — | $332.36 | $315.53 | -5.1% | -3.7% | +2.9% | +4.4% | +9.8% | -2.4% |
| Nov 7 | Citizens | Maintains | Market Outperform → Market Outperform | — | $332.36 | $315.53 | -5.1% | -3.7% | +2.9% | +4.4% | +9.8% | -2.4% |
| Oct 20 | Morgan Stanley | Maintains | Overweight → Overweight | — | $316.42 | $318.00 | +0.5% | +0.7% | -0.9% | -0.7% | -1.1% | +0.3% |
| Oct 8 | JP Morgan | Maintains | Overweight → Overweight | — | $341.62 | $347.82 | +1.8% | +2.8% | -4.4% | -4.7% | +2.2% | -1.9% |
| Aug 7 | RBC Capital | Maintains | Outperform → Outperform | — | $298.52 | $297.21 | -0.4% | -0.1% | -3.4% | +0.5% | -0.6% | +6.7% |
| Aug 7 | Guggenheim | Maintains | Buy → Buy | — | $298.52 | $297.21 | -0.4% | -0.1% | -3.4% | +0.5% | -0.6% | +6.7% |
| Jul 17 | JP Morgan | Maintains | Overweight → Overweight | — | $279.16 | $297.00 | +6.4% | +4.0% | +1.4% | -0.9% | +1.3% | -0.3% |
| Jul 16 | RBC Capital | Maintains | Outperform → Outperform | — | $269.70 | $272.99 | +1.2% | +3.5% | +4.0% | +1.4% | -0.9% | +1.3% |
| Jun 27 | JP Morgan | Maintains | Overweight → Overweight | — | $254.49 | $245.51 | -3.5% | -5.2% | +0.4% | +1.3% | -0.3% | +0.5% |
| Jun 27 | Morgan Stanley | Maintains | Overweight → Overweight | — | $254.49 | $245.51 | -3.5% | -5.2% | +0.4% | +1.3% | -0.3% | +0.5% |
| Jun 27 | RBC Capital | Maintains | Outperform → Outperform | — | $254.49 | $245.51 | -3.5% | -5.2% | +0.4% | +1.3% | -0.3% | +0.5% |
| May 8 | Guggenheim | Maintains | Buy → Buy | — | $232.25 | $236.28 | +1.7% | +1.6% | -1.7% | +0.5% | -3.7% | -2.1% |
| May 8 | RBC Capital | Maintains | Outperform → Outperform | — | $232.25 | $236.28 | +1.7% | +1.6% | -1.7% | +0.5% | -3.7% | -2.1% |
| Apr 28 | RBC Capital | Maintains | Outperform → Outperform | — | $244.90 | $247.67 | +1.1% | +1.9% | +0.1% | +4.0% | -1.6% | +0.1% |
| Apr 24 | TD Securities | Maintains | Buy → Buy | — | $249.13 | $257.88 | +3.5% | +2.8% | -4.4% | +1.9% | +0.1% | +4.0% |
| Apr 21 | JP Morgan | Maintains | Overweight → Overweight | — | $230.98 | $231.28 | +0.1% | -0.8% | +10.3% | -1.4% | +2.8% | -4.4% |
| Apr 16 | Guggenheim | Maintains | Buy → Buy | — | $238.84 | $235.00 | -1.6% | -4.5% | +1.2% | -0.8% | +10.3% | -1.4% |
| Apr 10 | Guggenheim | Maintains | Buy → Buy | — | $206.32 | $218.64 | +6.0% | +1.0% | +10.6% | +5.4% | -1.6% | -4.5% |
| Feb 28 | Macquarie | Maintains | Outperform → Outperform | — | $278.38 | $270.24 | -2.9% | -2.4% | -9.7% | +4.8% | +1.9% | -2.0% |
| Feb 28 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $278.38 | $270.24 | -2.9% | -2.4% | -9.7% | +4.8% | +1.9% | -2.0% |
| Nov 13 | TD Cowen | Maintains | Buy → Buy | — | $193.64 | $197.44 | +2.0% | +0.9% | -1.1% | -2.1% | -0.8% | +0.0% |
| Oct 22 | JP Morgan | Maintains | Overweight → Overweight | — | $219.92 | $219.14 | -0.4% | +0.3% | +0.2% | -3.1% | -0.6% | +2.1% |
| Aug 20 | JP Morgan | Maintains | Overweight → Overweight | — | $192.50 | $194.19 | +0.9% | +0.9% | +1.9% | -1.2% | -0.9% | +2.8% |
| Aug 8 | Citigroup | Maintains | Buy → Buy | — | $176.73 | $178.80 | +1.2% | +3.6% | -0.1% | +4.0% | -1.5% | -0.3% |
No insider trades available.
Data updated apr 26, 2026 5:27pm
· Source: massive.com